Redeye updates its fair value range following FlexQube’s Q3 report, which was weaker than expected. However, the order intake was better than in Q2 2023, and management seems hopeful that the trend should continue. Following FlexQube’s share issue in Q3 2023, we argue that the company should be funded until break-even in 2024, and we also see a potential catalyst in the commercial order intake for the Navigator in Q4 2023.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases